Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and ADhere. Thi...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2024-12, Vol.35 (1), p.2324833
Main Authors: Hebert, Adelaide A, Flohr, Carsten, Hong, H Chih-Ho, Irvine, Alan D, Pierce, Evangeline, Elmaraghy, Hany, Pillai, Sreekumar, Dawson, Zach, Chen, Sherry, Armengol, Clara, Siegfried, Elaine, Weidinger, Stephan
Format: Article
Language:English
Subjects:
Adolescent
Adolescents
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
atopic dermatitis
Child
Dermatitis, Atopic - drug therapy
Double-Blind Method
Drug Therapy, Combination
efficacy
Female
Humans
Injections, Subcutaneous
lebrikizumab
Male
Patient Reported Outcome Measures
quality of life
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and ADhere. This subset analysis evaluated 16-week physician- and patient-reported outcomes of lebrikizumab in the adolescent patients enrolled in these three trials. Eligible adolescents (≥12 to
ISSN:0954-6634
1471-1753
1471-1753
DOI:10.1080/09546634.2024.2324833